Encapsulation of methylene blue in polyacrylamide nanoparticle platforms protects its photodynamic effectiveness

The ability to prevent methylene blue (MB), a photosensitizer, from being reduced by plasma reductases will greatly improve its efficacy in photodynamic therapy (PDT) applications. We have developed a delivery approach for PDT by encapsulating MB using nanoparticle platforms (NPs). The 30-nm polyacr...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2008-05, Vol.369 (2), p.579-583
Main Authors: Tang, Wei, Xu, Hao, Park, Edwin J., Philbert, Martin A., Kopelman, Raoul
Format: Article
Language:English
Subjects:
Animals
Cell Line, Tumor
Drug Carriers - chemistry
Enzymatic reduction
Glioma - pathology
Glioma - therapy
Leukomethylene blue
Methylene blue
Methylene Blue - administration & dosage
Methylene Blue - chemistry
Nanoparticle platform
Nanoparticles - chemistry
Nanoparticles - ultrastructure
Photochemotherapy - methods
Photodynamic therapy
Polyacrylamide
Rats
Singlet oxygen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ability to prevent methylene blue (MB), a photosensitizer, from being reduced by plasma reductases will greatly improve its efficacy in photodynamic therapy (PDT) applications. We have developed a delivery approach for PDT by encapsulating MB using nanoparticle platforms (NPs). The 30-nm polyacrylamide-based NPs provide protection for the embedded MB against reduction by diaphorase enzymes. Furthermore, our data shows the matrix-protected MB efficiently induces photodynamic damage to tumor cells. The unprecedented results demonstrate the significant in vitro photodynamic effectiveness of MB when encapsulated within NPs, which promises to open new opportunities for MB in its in vivo and clinical studies.
ISSN:0006-291X
1090-2104
1090-2104
DOI:10.1016/j.bbrc.2008.02.066